| Expression pattern: |
UP |
| Associated gene: |
NAMPT, NAD+, PARP1 |
| Associated microRNA: |
hsa-miR-671-5p |
| Biological function: |
Regulates NAMPT expression and cellular NAD+ levels, affecting PARP1 PARylation and modulating sensitivity/resistance to Olaparib-based combination therapy in TMZ-resistant glioblastoma cells and organoids; serves as a predictive biomarker of drug response. |
| Molecular mechanism: |
May act through a miRNA-mediated mechanism involving hsa-miR-671-5p to influence NAMPT mRNA expression, thereby altering NAD+ levels and PARP1 PARylation; experimentally, circPTTG1IP overexpression/knockdown modulates NAMPT mRNA/protein and downstream NAD+/PARP activity. |
| Biological pathway or process: |
drug resistance (promotes); ceRNA regulation (other) |
| Detected method: |
Q
S
|
| Validation methods: |
RNA-seq; Bioinformatics Analysis; RT-qPCR; Transfection; CCK8; Western Blot; ROC Analysis; Clinical Sample Validation |
| Clinical significance: |
circPTTG1IP levels negatively correlate with Olaparib sensitivity and may serve as a marker to predict tumor response to the Olaparib/FK866/TMZ combination treatment (ROC AUC reported). |
| Description: |
In TMZ-resistant glioblastoma models, circPTTG1IP is upregulated upon Olaparib-containing treatment and modulates NAMPT expression, NAD+ levels, and PARP1 PARylation. Its level negatively correlates with Olaparib sensitivity and can be used as a predictive marker for response to the Olaparib/FK866/TMZ cocktail, potentially via a miRNA-mediated mechanism involving hsa-miR-671-5p. |
| Confidence score: |
0.6616 |